2-甲基-3-苯基甲氧基苯酚 | 79572-20-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-甲基-3-苯基甲氧基苯酚
• 英文名称: 2-benzyloxy-6-hydroxytoluene
• 英文别名: 3-(benzyloxy)-2-methylphenol；2-methyl-3-benzyloxyphenol；3-benzyloxy-2-methylphenol；2-methylresorcinol；2-methyl-3-phenylmethoxyphenol
• CAS: 79572-20-6
• 化学式: C₁₄H₁₄O₂
• 分子量: 214.264
• InChiKey: DBWJWQOMHAFTLT-UHFFFAOYSA-N

物化性质

• 沸点：
  361.3±27.0 °C(Predicted)
• 密度：
  1.134±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2909500000

反应信息

• 作为反应物：
  描述：

  2-甲基-3-苯基甲氧基苯酚 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 35.0h， 生成 2-(3-Methoxy-2-methyl-phenoxy)-propionic acid ethyl ester
  参考文献：
  名称：

  Potential antisecretory antidiarrheals. 2. .alpha.2-Adrenergic 2-[(aryloxy)alkyl]imidazolines

  摘要：

  Lofexidine, an alpha 2-agonist, has central hypotensive activity and peripheral intestinal antisecretory activity. Analogues were synthesized with increased polarity in an attempt to prevent penetration of the blood-brain barrier. The compounds were evaluated in the cholera toxin treated ligated jejunum of the rat and in the Ussing chamber with a rabbit ileum preparation. Active compounds were determined to be alpha 2-adrenergic agonists by yohimbine reversals of their Ussing chamber activities. The 2,6-dimethyl derivative of lofexidine, 4a, was as active as lofexidine in vivo, but derivatives with 2,6-substituents larger than ethyl were inactive. (Aryloxy)alkyl derivatives which have an imidazoline and a methyl or larger group as part of the alkyl exhibited the best antisecretory activity. Compounds with substituents in the para position of the phenyl ring were generally inactive. 3-Amino-2,6-dimethyl derivative 21 was twice as active as 4a. A 2-methyl substituent is required in the 3-amino series to retain good activity. 2-Methyl derivative 12a had activity comparable to that of 4a, while 6-methyl derivative 12f was inactive. Substituents on the 3-amino group did not affect the activity, but substituting a hydroxyl for the amino group produced an inactive compound. Replacing the phenyl moiety with a 4-indole resulted in retention of activity, but other heterocycles were inactive. Compound 12a was resolved and d isomer 32 was five times more potent than l isomer 33. The more active compounds in the rat cholera toxin assay (RCTA), when evaluated in the dog, exhibited antisecretory activity but also exhibited central nervous system (CNS) effects, sedation and ataxia, at 10 mg/kg, and in spontaneously hypertensive rats at 50 mg/kg. A measure of polarity, log P, was calculated for the (aryloxy)alkyl groups. Regression analysis showed no correlation of antisecretory ED50 to the calculated log P. The active compounds did not show a separation of the central CNS effects from the peripheral antisecretory activity by increasing the polarity.

  DOI：

  10.1021/jm00164a024
• 作为产物：
  描述：

  2,6-二羟基甲苯 在 potassium phosphate 、 sodium hydride 、 乙硫醇 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.33h， 生成 2-甲基-3-苯基甲氧基苯酚
  参考文献：
  名称：

  Suzuki, Tsuneo; Okada, Chizuko; Arai, Kenichi, Journal of Heterocyclic Chemistry, 2001, vol. 38, # 6, p. 1409 - 1418

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009062289A1

  公开（公告）日：2009-05-22

  Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

  公式I的化合物：其中c、R2、R3、R4、R5、R6、R7和R8按本说明定义，可用作HIV复制的抑制剂。
• Chemoselective Reactions of 3-Benzyloxy-1,2-<i>o</i>-Quinone with Organometallic Reagents
  作者：Luke A. Miller、Maurice A. Marsini、Thomas R. R. Pettus

  DOI：10.1021/ol9004068

  日期：2009.5.7

  Chemoselective additions of organometallic reagents to 3-benzyloxy-1,2-o-quinone are described. Various nucleophiles are shown to undergo selective 1,2-addition, 1,4-addition, and etherification. Selective 1,2-additions provide stable, nondimerizing o-quinols as a novel alternative to oxidative dearomatization.

  描述了有机金属试剂向3-苄氧基-1，2-邻苯醌的化学选择性加成。显示各种亲核试剂经历选择性的1，2-加成，1，4-加成和醚化。选择性的1，2-加成提供了稳定的，非二聚的邻喹啉，作为氧化脱芳烃作用的新型替代物。
• Piperazine derivatives
  申请人：Beecham Group Limited

  公开号：US04405620A1

  公开（公告）日：1983-09-20

  Compounds of the formula (I), or pharmaceutically acceptable salts thereof ##STR1## wherein X is phenyl, optionally substituted by one halogen, C.sub.1-4 alkyl or C.sub.1-4 alkoxy; or pyridyl; R.sub.1 is hydrogen or C.sub.1-6 alkyl; and n is 1 to 6, pharmaceutical compositions containing them and a process for their preparation. These compounds are useful in the prophylaxis or treatment of diseases due to a histamine-mediated allergic response.

  化合物的公式（I）或其药学上可接受的盐##STR1##其中X是苯基，可以选择性地被一个卤素，C.sub.1-4烷基或C.sub.1-4烷氧基取代；或者吡啶基；R.sub.1是氢或C.sub.1-6烷基；n为1至6，包含它们的药物组合物以及它们的制备方法。这些化合物在预防或治疗由组胺介导的过敏反应引起的疾病中很有用。
• [EN] AMIDINOHYDRAZONES AS PROTEASE INHIBITORS<br/>[FR] AMIDINOHYDRAZONES UTILISES EN QUALITE D'INHIBITEURS DE PROTEASE
  申请人：3-DIMENSIONAL PHARMACEUTICALS, INC.

  公开号：WO1997036580A1

  公开（公告）日：1997-10-09

  (EN) Amidino and benzamidino compounds, including compounds of formula (I), wherein R1-R4, R6-R9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of formula (I).(FR) Cette invention concerne des composés amidino et benzamidino, et notamment des composés correspondant à la formule (I) où R1-R4, R6-R9, Y, Z, n et m sont tels que définis dans la description. Cette invention concerne également des hydrates, des solvates ou des sels de ces composés acceptables sur le plan pharmaceutique, lesquels permettent d'inhiber des enzymes protéolytiques telles que la thrombine. Cette invention concerne également des procédés de préparation des composés correspondant à la formule (I).

  该专利描述了一类抑制蛋白酶酶活性的化合物，包括公式（I）中所述的R1-R4、R6-R9、Y、Z、n和m，以及其水合物、溶剂化合物或药学上可接受的盐。同时，该专利还描述了制备公式（I）中所述化合物的方法。
• Pharmacologically active benzopyranotriazole compounds
  申请人：Beecham Group Limited

  公开号：US04427686A1

  公开（公告）日：1984-01-24

  A compound of the formula (I): ##STR1## wherein R.sub.1 is hydrogen or C.sub.1-6 alkyl; R.sub.2, R.sub.3 and R.sub.4 are the same or different and are chosen from hydrogen, hydroxyl, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy and C.sub.1-4 alkanoyl; G is H or OH; and m and n are independently 1 to 3; with the proviso that when G is OH, one of m or n is 1; is useful in the prophylaxis and treatment of diseases whose symptoms are controlled by the mediators of the allergic response, for example asthma, hay fever, rhinitis and allergic eczema.

  化合物的式子（I）：其中R1为氢或C1-6烷基；R2、R3和R4相同或不同，选择自氢、羟基、卤素、C1-4烷基、C1-4烷氧基和C1-4酰基；G为H或OH；m和n独立地为1至3；但是当G为OH时，m或n之一为1。该化合物在预防和治疗那些由过敏反应介质控制的疾病的症状方面是有用的，例如哮喘、花粉症、鼻炎和过敏性湿疹。